The impact of viral bronchiolitis phenotyping: Is it time to consider phenotype-specific responses to individualize pharmacological management?
Antimicrobial Cationic Peptides
/ immunology
Bronchiolitis, Viral
/ drug therapy
Bronchodilator Agents
/ therapeutic use
Dermatitis, Atopic
/ immunology
Eosinophilia
/ blood
Guideline Adherence
Hospitalization
Humans
Microbiota
/ immunology
Phenotype
Picornaviridae Infections
/ drug therapy
Practice Guidelines as Topic
Respiratory Sounds
/ physiopathology
Respiratory Syncytial Virus Infections
/ drug therapy
Respiratory Syncytial Virus, Human
Rhinovirus
Th2 Cells
/ immunology
Cathelicidins
Bronchiolitis
Clinical practice guidelines
Phenotype-specific treatment
Viral bronchiolitis phenotyping
Journal
Paediatric respiratory reviews
ISSN: 1526-0550
Titre abrégé: Paediatr Respir Rev
Pays: England
ID NLM: 100898941
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
22
11
2018
revised:
11
03
2019
accepted:
05
04
2019
pubmed:
6
5
2019
medline:
29
6
2021
entrez:
6
5
2019
Statut:
ppublish
Résumé
Although recent guidelines recommend a minimalist approach to bronchiolitis, there are several issues with this posture. First, there are concerns about the definition of the disease, the quality of the guidelines, the method of administration of bronchodilators, and the availability of tools to evaluate the response to therapies. Second, for decades it has been assumed that all cases of viral bronchiolitis are the same, but recent evidence has shown that this is not the case. Distinct bronchiolitis phenotypes have been described, with heterogeneity in clinical presentation, molecular immune signatures and clinically relevant outcomes such as respiratory failure and recurrent wheezing. New research is critically needed to refine viral bronchiolitis phenotyping at the molecular and clinical levels as well as to define phenotype-specific responses to different therapeutic options.
Identifiants
pubmed: 31054799
pii: S1526-0542(18)30163-5
doi: 10.1016/j.prrv.2019.04.003
pmc: PMC7325448
mid: NIHMS1597258
pii:
doi:
Substances chimiques
Antimicrobial Cationic Peptides
0
Bronchodilator Agents
0
Cathelicidins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-58Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141237
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI130502
Pays : United States
Organisme : NHLBI NIH HHS
ID : R41 HL145669
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL141237
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
J Clin Virol. 2018 May;102:101-109
pubmed: 29549834
J Infect Dis. 2018 Mar 13;217(7):1160-1169
pubmed: 29293990
Expert Rev Respir Med. 2016 Aug;10(8):891-9
pubmed: 27192374
J Investig Med. 2018 Jan;66(1):46-51
pubmed: 28947640
Pediatr Res. 2018 Mar;83(3):606-614
pubmed: 29244796
Pediatr Allergy Immunol. 2018 Aug;29(5):555-557
pubmed: 29708628
Pediatrics. 2014 Nov;134(5):e1474-502
pubmed: 25349312
J Pediatr. 2003 Nov;143(5 Suppl):S127-32
pubmed: 14615711
Prim Care Respir J. 2007 Apr;16(2):93-7
pubmed: 17380234
Acta Paediatr. 2015 Sep;104(9):858-60
pubmed: 26014586
Implement Sci. 2009 Aug 12;4:54
pubmed: 19674440
Rev Infect Dis. 1991 May-Jun;13 Suppl 6:S454-62
pubmed: 1862276
Scand J Trauma Resusc Emerg Med. 2014 Apr 03;22:23
pubmed: 24694087
Biomed Res Int. 2017;2017:9730696
pubmed: 28758127
Arch Pediatr Adolesc Med. 2012 Dec;166(12):1155-64
pubmed: 23027409
Acta Paediatr. 2010 Jun;99(6):883-7
pubmed: 20163373
Can J Infect Dis Med Microbiol. 2016;2016:9139537
pubmed: 27840650
J Infect Dis. 2016 Mar 15;213(6):915-21
pubmed: 26508124
J Infect Dis. 2016 Aug 15;214(4):649-55
pubmed: 27190183
West J Emerg Med. 2015 Jan;16(1):85-8
pubmed: 25671015
Lancet. 2017 Jan 14;389(10065):211-224
pubmed: 27549684
J Pediatr. 1963 Dec;63:1205-7
pubmed: 14089830
Thorax. 2017 Jul;72(7):620-627
pubmed: 27531529
BMJ. 2015 Jun 02;350:h2305
pubmed: 26037525
J Allergy Clin Immunol. 2019 Apr;143(4):1371-1379.e7
pubmed: 30240701
J Allergy Clin Immunol. 2009 Apr;123(4):964-6
pubmed: 19181372
J Infect Dis. 2019 Jun 19;220(2):184-186
pubmed: 30783666
Thorax. 2016 Aug;71(8):712-8
pubmed: 27339060
Arch Pediatr Adolesc Med. 2012 Aug;166(8):700-6
pubmed: 22473882
J Allergy Clin Immunol. 2017 Feb;139(2):501-507
pubmed: 27312820
N Engl J Med. 2016 Jan 7;374(1):62-72
pubmed: 26735994
Pediatr Pulmonol. 2017 Sep;52(9):1234-1240
pubmed: 28672069
J Pediatr. 2016 May;172:202-204.e1
pubmed: 26875009
Pharmacoeconomics. 2004;22(5):275-84
pubmed: 15061677
J Asthma. 2013 Dec;50(10):1056-61
pubmed: 24000783
Paediatr Respir Rev. 2018 Jan;25:43-57
pubmed: 28258885
Arch Dis Child. 2010 Jan;95(1):35-41
pubmed: 19822538
Pediatrics. 2013 Oct;132(4):e810-6
pubmed: 24043283
West J Emerg Med. 2018 May;19(3):475-483
pubmed: 29760843
Am J Respir Crit Care Med. 2019 Jun 15;199(12):1456-1458
pubmed: 30657699
Pediatr Pulmonol. 2014 Mar;49(3):269-76
pubmed: 23401345
Paediatr Respir Rev. 2010 Mar;11(1):39-45; quiz 45
pubmed: 20113991
J Eval Clin Pract. 2017 Feb;23(1):37-43
pubmed: 26346971
J Pediatr. 2004 Aug;145(2):172-7
pubmed: 15289762
J Infect Dis. 2019 Jan 29;219(4):526-534
pubmed: 30204889
Pediatr Pulmonol. 2016 Dec;51(12):1330-1335
pubmed: 27228123
Am J Respir Crit Care Med. 2008 Oct 1;178(7):667-72
pubmed: 18565953
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
Lancet. 1993 Nov 27;342(8883):1317-22
pubmed: 7901634
AMIA Jt Summits Transl Sci Proc. 2014 Apr 07;2014:29-34
pubmed: 25717396
Pediatr Infect Dis J. 2013 Sep;32(9):950-5
pubmed: 23694832